Podcasts about cancer tumors

Send us Fan MailPatrick Coles, Ph.D., is the Chief Scientist at Normal Computing, where he develops novel computing hardware for Artificial Intelligence (AI) applications. Previously, he was a Staff Scientist at Los Alamos National Lab (LANL), where he made important contributions to the theory of quantum computing.Patrick has a broad background, having done his PhD in Chemical Engineering at Berkeley and his MPhil in Biochemistry at Cambridge. Currently, Patrick is working on a new theory for cancer and chronic disease. His Toxin Sequestration Theory (TST) of cancer was featured on the cover of the Masters Of Health magazine.He regularly discusses TST in his Substack blogs and his YouTube channel. He is also passionate about the carnivore diet, which he's been doing for 19 months now.Find Patrick at-YT- @OxalateWarriorSubstack- @patrickcolesTW- @ColesThermoAIFind Boundless Body at-myboundlessbody.comBook a session with us here! 

Lung cancer has a high chance of relapse, so how do we get out of ahead of it? Nancy Guo, SUNY Empire Innovation Professor in the school of computing at Binghamton University, discusses technology that helps us do so. Nancy Guo is one of the newest additions to the Binghamton University School of Computing as […]

SHOW CLIP: Dr. Bryan Ardis- Nicotine Patch for Cancer Tumors- 1 MIN CLIP MUST LISTEN by Kate Dalley

8 X Clips. Dan Bongino, Adam Carolla, National Guard in L.A., Al-Qaeda plans for numerous attacks on American soil, Covid 'Vaccines' Found in Cancer Tumors. Brittany Hughes.   Adam Carolla- National Guard troops to Los Angeles  Al-Qaeda has plans for numerous attacks on American soil. ShawnRyanShow Remarkable Cancer-Fighting Benefits of Ivermectin  unbelievable clown-show of government incompetence Adam Carolla: Everything is ‘gone as far as the eye can see' Dan Bongino has a very important message for you: “I give zero fcks about what you think” Top Scientist Sounds Alarm as Traces of Covid 'Vaccines' Found in Cancer Tumors The Brittany Hughes Show   Post The Adam Carolla Show @AdamCarollaShow Governor Newsom has deployed additional National Guard troops to Los Angeles in response to looting and fires.   Post RJ @realRJ2024 Sarah Adam's (Former CIA Analyst) talks about how Al-Qaeda has plans for numerous attacks on American soil. "The concept is the t*rrorist fights to the death, he will fight till either all of us are dead, or all of his people are dead" "We think its going to be a swarming attack, multiple different attacks at the same time across multiple cities" These bad actors from a whole different country are coming to America to cause mass casualties. We need to be ready because its coming and it feels like its just getting started! @ShawnRyanShow @ShawnRyan762     Post “Sudden And Unexpected” @toobaffled The Remarkable Cancer-Fighting Benefits of Ivermectin • “Ivermectin can actually kill cancer stem cells,” which are often resistant to chemotherapy. • “It can also reverse resistance that cancer cells develop to chemotherapy,” making treatments more effective. • “It makes cancer cells susceptible to radiation treatment as well. And so it's a radiosensitizer.” • Patients are seeing “tumors shrinking down to almost nothing, liver metastases disappearing, [and] brain metastases disappearing.” “There are over 100 papers on the success of ivermectin and cancer,” but much of this research has been ignored because the drug is off-patent, meaning “no one's going to make money on it.” Dr. Makis has treated over 1,000 patients using combinations of ivermectin, fenbendazole, and other therapies. Many of his patients, told by their doctors that there was “nothing they can do for them,” are now “cancer-free” or have their “cancer under control.” The success stories are undeniable, and the hope is spreading. @MakisMD     Post Peter St Onge, Ph.D. @profstonge Democrats in California burned down their state. Again. Projections are up to $150 billion in destruction and an almost unbelievable clown-show of government incompetence.   Adam Carolla: Everything is ‘gone as far as the eye can see' Fox News 12.7M subscribers 656,543 views Jan 10, 2025 #foxnews 656,543 views • Jan 10, 2025 • #foxnews ‘The Adam Carolla Show' host Adam Carolla joins ‘Gutfeld!' to talk about the California wildfires. #foxnews   Post MAGA Voice @MAGAVoice Dan Bongino has a very important message for you: “I give zero fcks about what you think” LET'S FREAKING GO BOOM   Post Jessica Rojas  @catsscareme2021 Wow! A must watch. This will blow you away. "Top Scientist Sounds Alarm as Traces of Covid 'Vaccines' Found in Cancer Tumors" realbritthughes Brittany M. Hughes Managing Editor of MRCTV. Host of @mediaresearchcenter podcast “The Brittany Hughes Show”. linktr.ee/realbritthughes https://www.instagram.com/realbritthughes/?fbclid=IwY2xjawH1Ee9leHRuA2FlbQIxMAABHS0x_eD1jIPHa1a5D-pSaIxspMDrgf850j8tdw5cr_Zcr5UCCowYAa96Bw_aem_EXiRIqAZeUHxQlNVdtS80g

'THE RAW DOG FOOD TRUTH' PODCAST YOUR PET'S HEALTH IS OUR BUSINESS FRIENDS DON'T LET FRIENDS FEED KIBBLE DeDe and Dr Judy Jasek talk about the Traditional and Holistic Path for Cancer Patients   10:45 - Fear sells - how to break free from the fear tactics 24:00 Tumors in Liver what to expect from traditional methods vs. holistic treatments Species Appropriate Diets are a must for optimal health www.RawDogFoodandCompany.com

#51 Dr. Kenneth Tomkovich and Jess chat about pioneering cryoablation for breast cancer tumors. Cryoablation is defined as using extreme cold (cryo) to distroy (ablate) tissue from the inside out. His work in cryoablation for breast cancer serves the patient with a gentler way to treat breast cancer tumors as compared to a traditional lumpectomy. Cryoablation is minimally invasive, less stressful on the patient, less recovery time, and no disfigurement. In most cases, a patient can have their ablation proceedure and then go out to lunch right after. Listen/watch for much more of our great chat on One Take with Jess.

Tune in to hear how EKTA's most recent research sparked a journey to discovering a breakthrough drug target that has been shown to help shrink skin tumors when it is blocked by pharmaceutically engineered molecules that block the protein known as AQUAPORIN 3 (AQP3) ! --- Send in a voice message: https://anchor.fm/skincareanarchy/message Support this podcast: https://anchor.fm/skincareanarchy/support

Brother Carlos & More --- Send in a voice message: https://anchor.fm/aei-leon/message Support this podcast: https://anchor.fm/aei-leon/support

******************** Aimee Powell is a patient advocate working with patients with paraganglioma/pheochromocytoma, rare neuroendocrine tumors. She is the founder of the Pheo Para Project and past Executive Director of the Pheo Para Alliance, and currently sits on the board of directors for the SDH-Deficient Cancer Research Advocates. Aimee currently lives in the Greater Los Angeles area. A paraganglioma is a rare neuroendocrine neoplasm that may develop at various body sites. When the same type of tumor is found in the adrenal gland, they are referred to as a pheochromocytoma. They are rare tumors, with an overall estimated incidence of 1/300,000. Unlike other types of cancer, there is no test that determines benign fr... www.pheoparaproject.org www.sdhcancer.org "A journey of a thousand miles begins with a single step." --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/justchatwitbri/support

Dr. Bill Audeh, medical oncologist and Chief Medical Officer, Agendia left his 30 year career of medical practice treating breast cancer patients to join Agendia because of the exciting opportunities for precision medicine to treat breast cancer. With technology that allows for genomic testing of the cancer tumors, it can be determined how likely it is that the cancer could spread and identifies what's driving the cancer's growth.  With this data, physicians can be informed about the best treatment for each individual patient. @agendia #precisionmedicine #genomictesting #breastcancer Agendia.com Download the transcript here

Dr. Bill Audeh, medical oncologist and Chief Medical Officer, Agendia left his 30 year career of medical practice treating breast cancer patients to join Agendia because of the exciting opportunities for precision medicine to treat breast cancer. With technology that allows for genomic testing of the cancer tumors, it can be determined how likely it is that the cancer could spread and identifies what's driving the cancer's growth.  With this data, physicians can be informed about the best treatment for each individual patient. @agendia #precisionmedicine #genomictesting #breastcancer Agendia.com Listen to the podcast here

The cover for issue 44 of Oncotarget features Figure 1, "Schematic diagram of the human IGF2 gene structure," by Radhakrishnan, et al. recently published in "Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells" which reported that these authors previously demonstrated that IGF2 protein levels are higher in BC tissues from African American women than in Caucasian women. They also showed that high IGF2 protein levels are expressed in normal breast tissues of African American women while little or no IGF2 was detected in tissues from Caucasian women. Thus, they designed this study to determine if differentially methylated regions of the IGF2 gene correspond to IGF2 protein expression in paired breast tissues and in BC cell lines. The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer. Since IGF2 promotes metastasis and chemoresistance, we propose that IGF2 levels contribute to BC aggressiveness. Dr. Daisy D. De León from The Loma Linda University School of Medicine said, "Insulin-Like Growth factor 2 (IGF2) is a fetal growth factor that plays a critical function in fetal differentiation and metabolism by signaling through the IGF-I receptor and the insulin receptor." Thus, IGF2 expression is important in normal breast development and increased IGF2 expression in the mammary gland contributes to BC malignancy. This gene is located on the short arm of chromosome 11 at position 15.5. Methylation of the IGF2 gene regulatory regions occurs during the formation of an egg or sperm cell, and it is distinct and differentially modified depending on the parental origin of the allele. In particular, dysregulation in the methylation of the IGF2 gene promoters occurs in several cancers including BC and this altered methylation leads to different clinical features in BC disease. In spite of these advances, there is currently no consensus regarding the methylation status of the IGF2 gene, and its relationship to the levels of IGF2 protein expressed in normal breast or in breast cancer tissues. DNA methylation patterns of the IGF2 gene were also analyzed in several BC cell lines to determine if there was a correlation between methylation of the IGF2 gene regulatory regions and the cellular expression levels of IGF2 protein. The De León Research Team concluded in their Oncotarget Research Paper, "the present study shows that IGF2 expression in BC cells and in paired Normal- Malignant breast tissues are determined by the methylation of a novel region in the INS-IGF2 locus. We are currently studying the mechanisms underlying the methylation of the INS-IGF2 and how they control IGF2 expression. Upregulation of IGF2 in terms of the methylation patterns of the DVDMR may have an important function in the tumorigenesis of the breast. In conclusion, we propose that the INS-IGF2 DVDMR may be a useful tool to identify women at risk of developing a more aggressive BC disease." Sign up for free Altmetric alerts about this article DOI - https://doi.org/10.18632/oncotarget.27655 Full text - https://www.oncotarget.com/article/27655/text/ Correspondence to - Daisy D. De León - ddeleon@llu.edu Keywords - IGF2, INS-IGF2, hypermethylation, DMR, epigenetics About Oncotarget Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/

Guest: Putao Cen, MD Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

Guest: Putao Cen, MD Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

In this clip from our show 'Believe', we discuss "Health & Wellness". Scientists Destroy Cancer Tumors with Sound Waves & Frequencies - Rife Machine Reborn? Hosted by: Nicholas Upchurch Our website: http://www.believe.love

Dr. Vineet Choudhry, MD is a general surgery specialist in Austin, TX and has been practicing for 10 years. He graduated from The Texas A&M University System Health Science Center College Of Medicine in 2003 and specializes in general surgery. Dr. Choudhry discusses clinical trials, specifically cryoblation treatment and the FROST clinical trial which freezes early stage breast cancer.

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

J. Craig Venter, founder, chair and CEO of the J. Craig Venter Institute and co-founder of two private genomics companies, recounts his breakthroughs in genome sequencing and shares new research on fighting cancer tumors with personalized vaccines. Venter is presented by the Altman Clinical and Translational Research Institute at UC San Diego. Series: "Wellbeing " [Health and Medicine] [Professional Medical Education] [Show ID: 31734]

Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.

Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.

Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.